Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Emergency contraception OTC

Executive Summary

Women's Capital Corporation's application to switch its Plan B emergency contraceptive from Rx to OTC status is expected to be considered by FDA's Nonprescription Drugs and Reproductive Health Drugs Advisory Committees in mid-December. Both committees are tentatively scheduled to meet Dec. 16. A switch application for Plan B was filed April 21...

You may also be interested in...



Barr’s women’s health strategy goes to Plan B

Barr acquires Women's Capital Corporation's emergency oral contraceptive Plan B. The company will continue to pursue over-the-counter status for Plan B; the emergency contraceptive is expected to be considered by FDA's Nonprescription Drugs & Reproductive Health Drugs Advisory Committees in mid-December (1"The Pink Sheet" Sept. 29, 2003, In Brief). Barr will also acquire "certain other assets and liabilities" from WCC...

Second EU MDR Notified Body Designated In France

Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.

Takeda, Astellas Found New JV To Support Japanese Bioventures

Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042526

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel